What is EQUASHIELD?
Founded in 2009, EQUASHIELD specializes in advanced compounding technology, focusing on the development and deployment of automated compounding robots and closed system transfer devices. The company's innovative solutions are engineered to mitigate the risks associated with handling hazardous drugs, thereby enhancing safety protocols within healthcare environments. This strategic focus positions EQUASHIELD as a key player in a critical niche of the healthcare technology sector.
How much funding has EQUASHIELD raised?
EQUASHIELD has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in EQUASHIELD
PPP
Public-Private Partnership
What's next for EQUASHIELD?
The recent major strategic investment signals a new phase of growth and development for EQUASHIELD. This capital is expected to fuel further innovation in their automated compounding and closed system transfer device technologies, potentially expanding their market reach and enhancing their product offerings. The company is poised to leverage this backing to solidify its position as a leader in healthcare worker safety, driving advancements in a sector with increasing demand for robust protective solutions.
See full EQUASHIELD company page
